免疫チェックポイント阻害剤の米国食品医薬品局承認における免疫関連の有害事象の報告

Shaili Tapiavala1, Chongliang Luo2, Mina Shenouda3

  • 1Division of Oncology, Washington University in St. Louis, St. Louis, MO, United States.

Frontiers in oncology
|August 29, 2025
PubMed
まとめ

免疫チェックポイント阻害剤 (ICI) の臨床試験における免疫関連の有害事象 (irAEs) の報告は,特に希少な事象では一貫していない. ICIの毒性を明確に伝えるためには,報告の標準化が不可欠です.

関連する概念動画

Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
983
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.8K